SCHEMBL3533352

SCHEMBL3533352

CN1CCN(c2ccc3nc(-c4n[nH]c5cccc(NS(=O)(=O)c6ccccc6)c45)[nH]c3c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 12/20 0.61
FLT1 P17948 8/20 0.61
PDPK1 O15530 2/20 0.52
PDGFRB P09619 6/20 0.51
KDR P35968 6/20 0.51
FLT3 P36888 2/20 0.46
CDK4 P11802 2/20 0.46
ABL1 P00519 2/20 0.46
PLK4 O00444 1/20 0.46
STK25 O00506 1/20 0.46
CIT O14578 1/20 0.46
RIOK3 O14730 1/20 0.46
CHEK1 O14757 1/20 0.46
GAK O14976 1/20 0.46
CHUK O15111 1/20 0.46
MUSK O15146 1/20 0.46
EPHB6 O15197 1/20 0.46
MAP3K13 O43283 1/20 0.46
DAPK3 O43293 1/20 0.46
MAP3K7 O43318 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3537022 0.91 FGFR1 (0.55) FGFR1FLT1PDPK1PDGFRBKDR
SCHEMBL3545051 0.90 FGFR1 (0.63) FGFR1FLT1PDPK1PDGFRBKDR
SCHEMBL3541407 0.88 FGFR1 (0.63) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL3535462 0.87 FGFR1 (0.59) FGFR1FLT1PDPK1PDGFRBKDR
SCHEMBL29009493 0.87 FGFR1 (0.59) FGFR1FLT1PDPK1PDGFRBKDR
SCHEMBL3544750 0.86 FGFR1 (0.70) FGFR1FLT1KDRABL1BCR
SCHEMBL3540489 0.85 FGFR1 (0.67) FGFR1FLT1PDGFRBKDRFLT3
SCHEMBL3536231 0.83 FGFR1 (0.61) FGFR1FLT1PDPK1PDGFRBKDR
SCHEMBL3540208 0.83 FGFR1 (0.67) FGFR1FLT1PDPK1PDGFRBKDR
SCHEMBL3537564 0.83 PDPK1 (0.63) FGFR1FLT1PDPK1PDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885PDPK1 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.